Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced that management will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10 at 7:00 a.m. Eastern Time. The presentation can be accessed via the company's website in the Investors and Media section and will be available for viewing post-event. Sangamo focuses on genomic medicine using proprietary zinc finger genome engineering technologies to develop new treatments for diseases lacking adequate options.
Pfizer (NYSE: PFE) and Sangamo Therapeutics (NASDAQ: SGMO) have released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy for severe hemophilia A. At 104 weeks, patients in the highest dose cohort exhibited a mean factor VIII activity of 25.4% with no annualized bleeding in the first year post-infusion. However, the Phase 3 AFFINE trial has encountered a clinical hold by the FDA following observations of elevated FVIII levels in treated patients. The ongoing studies aim to evaluate long-term efficacy and safety of this investigational therapy.
Sangamo Therapeutics announced positive preliminary data from its Phase 1/2 PRECIZN-1 study of SAR445136, a gene-edited cell therapy for sickle cell disease (SCD). All four treated patients showed increased total hemoglobin and fetal hemoglobin, with none requiring blood transfusions post-engraftment. The longest-treated patient was followed for 91 weeks. The safety profile was favorable, with no adverse events linked to SAR445136. These findings highlight the therapeutic potential of zinc finger nuclease technology in addressing unmet needs in SCD.
Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in several upcoming investor conferences. Management will present at the Barclays Gene Editing & Gene Therapy Summit on November 15 at 10:30 a.m. Eastern Time, followed by the Stifel 2021 Virtual Healthcare Conference on the same day at 3:20 p.m. Eastern Time. Additionally, they will participate in the Jefferies London Healthcare Conference on November 16 at 8:40 a.m. Eastern Time. Presentations will be webcasted live and available later on Sangamo's website.
Sangamo Therapeutics (SGMO) reported its Q3 2021 financial results, revealing a net loss of $47.7 million or $0.33 per share, a significant increase from a loss of $1.6 million in Q3 2020. Revenue dropped to $28.6 million, down from $57.8 million, mainly due to reduced collaboration revenue with Pfizer. Key clinical updates include positive data from its Fabry disease and hemophilia A programs, with plans for a Phase 3 trial for Fabry disease. Additionally, preliminary results for its sickle cell disease therapy will be shared at the ASH meeting in December.
Sangamo Therapeutics has announced promising preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. All four patients in the initial cohorts showed above-normal α-Gal A activity, maintained for up to one year. The company is planning a Phase 3 trial following these results, with one patient withdrawing from enzyme replacement therapy due to stable enzyme activity. There were no Grade 2 or higher adverse events reported.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced the release date for its third quarter 2021 financial results, set for November 4, 2021. Following the release, a conference call is scheduled at 9:15 a.m. ET, open to the public through telephone and webcast. Key details include dial-in numbers and a conference ID for participants. Sangamo is a clinical-stage biopharmaceutical firm focused on genomic medicines, leveraging proprietary technology to develop solutions for patients with unmet medical needs. For more information, visit sangamo.com.
Sangamo Therapeutics (NASDAQ: SGMO) has announced its participation in upcoming investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference is scheduled for September 10 at 3:20 p.m. ET. Next, at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, Sangamo will present on September 13 at 7:00 a.m. ET. Lastly, the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 15 at 10:15 a.m. ET. Presentations will be available for webcasting and later on Sangamo's website under Events and Presentations.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on August 11 at 2:55 PM Eastern Time. The virtual session will be webcast live, providing investors access to insights about the company's genomic medicines pipeline, which leverages zinc finger genome engineering technology. The presentation will be available for later viewing on Sangamo's website, ensuring that stakeholders can stay informed about its progress and strategies in the clinical-stage biopharmaceutical sector.
Sangamo Therapeutics (SGMO) announced its Q2 2021 financial results, reporting a net loss of $47.2 million or $0.33 per share, up from a loss of $35.9 million in 2020. Q2 revenues reached $27.9 million, a $6.3 million increase year-over-year, attributed to collaboration agreements with Novartis and Biogen. Operating expenses rose to $76.6 million from $59.4 million in Q2 2020. As of June 30, 2021, cash and equivalents totaled $578.9 million. The company reiterated its 2021 expense guidance of $285 million to $305 million.